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Abstract
Neuronal  hyperexcitability  is  a  well-known  phenomenon  in  amyotrophic  lateral
sclerosis  and  other  neurodegenerative  diseases.  The  use  of  transcranial  magnetic
stimulation in clinical and research practice has recently made it possible to detect motor
cortex  hyperexcitability  under  clinical  conditions.  Despite  numerous  studies,  the
mechanisms and sequelae of the development of hyperexcitability still have not been
completely elucidated. In this chapter, we discuss the possibilities for detecting motor
cortex hyperexcitability in patients with amyotrophic lateral sclerosis using transcrani‐
al  magnetic  stimulation.  The  potential  relationship  between  hyperexcitability  and
neuronal degeneration or neuroplasticity processes is discussed using the data obtained
by navigated transcranial magnetic stimulation and neuroimaging data, as well as the
data of experimental studies.
Keywords: transcranial magnetic stimulation, amyotrophic lateral sclerosis, hyperex‐
citability, excitotoxicity, neuroplasticity
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease affecting the upper
and lower motor neurons. Despite the significant advance in molecular biology and genetics
over the past years, many aspects of etiology and pathogenesis of ALS remain unstudied;
neither biomarkers of the disease nor effective treatment methods have been designed [1].
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A significant advance in understanding the pathophysiological mechanisms of the develop‐
ment of the neurodegenerative process of ALS has been made over the past years after novel
neurophysiological and neuroimaging techniques were introduced into the research and
clinical practice [2–4]. Transcranial magnetic stimulation (TMS) is a noninvasive brain
stimulation method that is used to evaluate the functional status of the upper motor neuron
in ALS patients. It has been shown in the recent studies that different TMS parameters are
altered in ALS patients [4]. TMS is currently viewed as a valuable research and diagnostic tool
in ALS.
Development of hyperexcitability of the primary motor cortex and the entire motor system is
a well-studied phenomenon in ALS. Motor cortex hyperexcitability can be determined using
TMS as reduced resting motor threshold and increased motor evoked potential (MEP)
amplitude, decreased silent period, reduced effectiveness of short-interval intracortical
inhibition (SICI), and increased intracortical facilitation (ICF) (see review [4]). Most authors
attribute motor cortex hyperexcitability in ALS patients to enhanced glutamatergic neuro‐
transmission in the neocortex and reduced gamma-aminobutyric acid (GABA)ergic inhibitory
neurotransmission, thus suggesting that hyperexcitability provokes degeneration of motor
neurons [5–7]. However, no direct evidence has been obtained yet that would unambiguously
demonstrate the relationship between motor cortex hyperexcitability in ALS patients and its
degeneration. There is an alternative opinion that hyperexcitability can potentially be related
to neuroplasticity processes taking place in the motor cortex and compensation for the lost
function.
We would like to discuss the potential relationship of motor cortex hyperexcitability with
motor neuron degeneration and neuroplasticity in ALS patients, as well as the possible
methods to solve this problem using modern neurophysiological and neuroimaging methods.
2. Motor cortex hyperexcitability in ALS
Although the term ‘hyperexcitability’ is widely used, it still does not have a commonly
accepted definition. According to Bae et al. (2013), it ‘means an increased or exaggerated
response to a stimulus, which may usually have been expected to evoke a normal response’
[7]. We deem that hyperexcitability is discussed in modern TMS studies more broadly: as the
ability to respond to stimuli that normally do not evoke any response and, speaking more
generally, as the predominance of excitation over inhibition.
Hyperexcitability in ALS patients can be determined using various methods at different levels
of the motor system. It can be detected at the level of individual neurons and ion channels in
cell cultures in transgenic animals, clinically (presenting as the well-known phenomena, such
as fasciculation or cramps) or using the modern neurophysiological techniques such as
electromyography (EMG) and TMS [7].
Motor cortex excitability is a complex integral parameter that depends on numerous factors.
Hence, the hyperexcitability phenomenon is also a complex and multifactorial process that
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depends on glutamate synthesis and release, its reuptake and degradation, expression and
functional status of several types of glutamate receptors, excitable properties of neuronal
membranes, and the status of inhibitory GABAergic neurotransmission. A number of experi‐
mental studies demonstrated that all the aforementioned processes are disturbed in ALS [8,
9]. Table 1 summarizes the results of some key studies.
Mechanism Supporting facts
Decreased
Glutamate reuptake
• A 70-80% decrease in expression of high-affinity astroglial glutamate transporter EAAT2
(excitatory amino acid transporter) in the motor cortex and spinal cord in ALS patients as
a result of posttranslational modifications, oxidative stress, and other factors [10, 11]
• Early reduction of glutamate transporter expression in mSOD1 transgenic animals [12]
• Degeneration of motor neurons in the motor cortex and spinal cord as glutamate reuptake
is inhibited in vitro in an organotypic cell culture [13]
• The absence of compensatory increase in glutamate transporter expression by glial cells
under excitotoxic conditions and oxidative stress [14]
Dysfunction of
inhibitory GABAergic
neurotransmission
• Degeneration of inhibitory interneurons in the motor cortex and spinal cord in ALS patients
according to pathomorphological and animal model studies [15–17]
• Decreased GABA level in the motor cortex according to the MR spectroscopy [18] and
reduced 11C-flumazenil binding according to the PET data [19]
• Decreased level of mRNA of GABA(A) receptor subunits in a postmortem study [20]
Changes in excitability
of motor neuron
membranes
• Increased density and excitability of voltage-gated sodium channels in SOD1 transgenic
animals [21, 22]
• Decreased conductance of potassium channels Kv 1.2
• Hyperexcitability of individual motor neurons in a cell culture [23, 24]
Changes in expression
and functions of
glutamate receptors
• Decreased expression of the GluR2 subunit blocking calcium delivery to the cell in ALS
patients with transgenic animals [25]
• Disturbance of posttranslational modification of GluR2 subunit increasing permeability to
calcium ions [25]
Table 1. Potential mechanisms of development of motor neuron hyperexcitability in ALS patients.
Today, TMS is the key and actually the only method for clinical investigation of motor cortex
excitability. The use of the entire range of TMS parameters allows one to perform a relatively
differentiated study of various factors contributing to motor cortex excitation [26]. TMS can
be employed for assessing the functional status of the corticospinal tract due to the ability to
excite motor cortex neurons by induced electrical current followed by propagation of excitation
to alpha motor neurons of spinal cord. This causes contraction of muscle fibers within a certain
motor unit, which can be recorded by cutaneous electrodes as a MEP [27]. TMS assesses the
functional status of neuronal contours of the motor cortex [28].
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Motor threshold is the key parameter used to assess motor cortex excitability. The motor
threshold represents the density of corticospinal projections and can be regarded as a bio‐
marker of neuronal membrane excitability [26]. Decreased motor threshold is considered to
be one of the key signs of motor cortex hyperexcitability.
According to most studies, the motor threshold in ALS patients is increased, probably being
indicative of degeneration of cortical motor neurons [29–35]. Meanwhile, a paradoxical
decrease in the motor threshold when examining patients at the onset of the disease was shown
in some studies [36–39]. The motor threshold is likely to decrease at the onset of ALS, probably
until clinical signs appear, and subsequently increases as motor neurons die. A statistically
significant direct correlation between the motor threshold and disease duration was demon‐
strated in some studies [29, 40].
Physiologically, the motor threshold is primarily determined by rapid AMPA receptor
(AMPAR)-mediated glutamatergic neurotransmission in the neocortex and excitability of
motor neuron membranes that depends on voltage-gated sodium channels [41]. In ALS, AMPA
receptor-mediated glutamatergic neurotransmission increases and properties of sodium
channels change (presenting as increased conductance) [23, 24, 42, 43]. Alteration in functional
properties of potential-gated sodium channels has been revealed: more rapid recovery after
inactivation, increased permeability to sodium, and increased density of ion channels [21].
Pieri et al. demonstrated a decrease in the action potential threshold, an increase in pulse
frequency, and an increase in persistent sodium current in cortical motor neurons isolated in
G93A mutant mice [22].
MEP amplitude is determined by the number of reduced motor units and the number of
activated alpha motor neurons in the spinal cord. Increased stimulation intensity enhances
MEP amplitude due to superimposition of late I-waves and I1-wave [28, 44]. Like the motor
threshold, MEP amplitude is determined by the density of corticospinal projections. Mean‐
while, MEP amplitude to a greater extent represents the function of neurons with lower
excitability or those located farther from the stimulation site [4]. GABAergic drugs reduce MEP
amplitude, which results from the scheme of generation of late I-waves modulated by inserted
inhibitory GABAergic interneurons [41]. Noteworthy, the motor threshold and MEP ampli‐
tude are modulated by drugs belonging to different pharmacological classes, thus emphasiz‐
ing the difference between the mechanisms of their formation.
Identically to the motor threshold, MEP amplitude in ALS patients changes in opposite
directions depending on stage of the disease. MEP amplitude decreases in most cases, being
accompanied by increased motor threshold and representing a decrease in motor neuron
number and reduction of density of corticospinal projections [4]. On the contrary, some
patients with the reduced motor threshold may have increased MEP amplitude and the ratio
between MEP amplitude and M-response amplitude [45, 46]. The increased slope ratio of the
amplitude vs intensity curve is additional evidence to motor cortex hyperexcitability in ALS
patients as it demonstrates a more pronounced amplitude increment with increasing stimu‐
lation intensity compared to the norm. The increase in MEP amplitude and the slope ratio of
the amplitude vs intensity curve in ALS patients is probably related to both enhanced
glutamatergic and reduced inhibitory GABAergic neurotransmission in the neocortex [4].
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The cortical silent period (cSP) represents inhibition of voluntary muscular activity during a
certain period after a magnetic stimulus was applied [47]. It has been demonstrated that the
first one-third of cSP is mostly controlled by inhibitory mechanisms at the spinal cord level,
while the remaining two thirds are of cortical origin and are related to inhibitory neurotrans‐
mission through GABA(B) receptors [27].
It was demonstrated in most studies that patients with sporadic and familial ALS had either
decreased cSP or no cSP at all, which is regarded as significant evidence attesting to intracort‐
ical inhibitory dysfunction in ALS patients [48–50].
Paired pulse stimulation is used to assess intracortical inhibition and excitation processes. The
method involves sequential generation of two pulses: the conditioning (S1) and testing (S2)
pulses. The physiological effects of paired pulse stimulation are determined by the intensity
of S1 and the interval between S1 and S2 pulses. Application of the sub-threshold S1 pulse 1–
6 ms before the supra-threshold S2 pulse reduces MEP amplitude compared to isolated
application of a supra-threshold stimulus [51]. This phenomenon is known as SICI. Contrari‐
wise, an increase of the interstimulus interval to 8–20 ms rises the amplitude of MEP to the
testing pulse (ICF). Several protocols have been proposed where the conditioning pulse has
the supra- and sub-threshold intensity. MEP amplitude increases at the long interstimulus
interval (long-interval intracortical inhibition, LICI) and decreases at the short interval (short-
interval intracortical facilitation, SICF) [27].
The neurophysiological mechanisms of formation of these phenomena remain insufficiently
studied; however, it has been demonstrated rather convincingly that they have the predomi‐
nantly intracortical origin. Thus, SICI and LICI protocols cause suppression of amplitude and
the number of late descending waves [51, 52]. Intracortical inhibition processes are assumed
to be caused by activation of neocortical inhibitory interneurons under the action of the
conditioning pulse; SICI being mediated by inhibition through GABA(A) receptors and LICI,
through GABA(B) receptors. The ICF phenomenon is presumably caused by activation of
glutamatergic neurotransmission through NMDA glutamate receptors [26].
Disruption of intracortical inhibition and facilitation under paired-pulse stimulation is
currently believed to be the most convincing evidence that motor cortex hyperexcitability
develops in ALS patients and has been detected in numerous studies [6, 53, 54, 55]. It should
be mentioned that a decrease in efficiency of SICI is revealed at the earliest stages of the disease,
including asymptomatic SOD1 mutation carriers, and correlates with axonal degeneration of
peripheral motor neurons [45]. Assessment of the disruptions of intracortical inhibition using
the new threshold tracking technique is considered to be a potential diagnostic tool in ALS
demonstrating high sensitivity and specificity [56, 57].
The role of inhibitory interneurons dysfunction in pathogenesis of ALS has been actively
studied over the past years [58–60]. Degeneration of inhibitory interneurons both in the spinal
cord and in the motor cortex was demonstrated in several pathomorphological studies carried
out in the 1990s. Nihei et al. (1993) reported a reduced amount of parvalbumin-positive
interneurons in the motor cortex in ALS patients [61]. In addition, Petri et al. (2003) demon‐
strated that the level of GABA(A) receptor alpha-1 subunit mRNA decreases in ALS patients
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[20]. Dysfunction of inhibitory neurotransmission in the neocortex has also been confirmed in
neuroimaging studies presenting as a decrease in GABA amount according to magnetic
resonance spectroscopy [18] and decreased 11C-flumazenil binding as shown by PET [19].
The TMS data additionally confirm that inhibitory neurotransmission in the neocortex is
disrupted in ALS patients. It should be mentioned that TMS has been used to show the
disturbance of inhibition in the motor cortex both mediated by GABA(A) (decreased SICI) and
by GABA(B) receptors (decreased LICI and sCP), being indicative of degeneration of inter‐
neurons or GABA metabolism disruption rather than dysfunction of receptors of this mediator
in the postsynaptic membrane.
Other factors that cause SICI disruption in ALS patients are being discussed. Thus, riluzole
was reported to induce partial recovery of SICI in ALS patients, which gives grounds for
suggesting that enhancement of glutamatergic neurotransmission plays a role in disturbance
of intracortical inhibition in ALS patients. NMDA receptor antagonists, memantine and
amantadine, were shown to increase SICI and decrease ICF in several pharmaco-TMS studies
[41]. These data suggest that decreased intracortical inhibition in ALS patients can be related
not only to reduction of inhibitory GABAergic neurotransmission but also to enhancement of
glutamatergic neurotransmission through NMDAR.
Increased intracortical facilitation is another evidence for involvement of NMDAR in patho‐
genesis of ALS. This phenomenon is currently predominantly attributed to glutamatergic
neurotransmission through NMDAR, which is confirmed, in particular, by its reduction due
to antagonists of these receptors [41].
Hence, a large body of data attesting to the development of motor cortex hyperexcitability in
ALS patients can currently be obtained by TMS. Signs attesting to degeneration of the upper
motor neuron are detected simultaneously (Table 2). Importantly, some TMS parameters
(MEP threshold and amplitude) can change in opposite directions and attest to motor cortex
hyperexcitability at onset of the disease and degeneration as the disease progresses. Mean‐
while, such signs of hyperexcitability as decreased cSP and efficiency of SICI are detected even
in patients with pronounced degeneration of motor neurons. This phenomenon in ALS
patients was referred to as ‘dying but overactive’ [7]; it can cause difficulties for interpretation
of TMS results in a specific patient.
Hyperexcitability Degeneration
• Resting motor threshold decreased
• MEP amplitude increased
• SICI reduced and ICF increased
• SP decreased
• Resting motor threshold increased
• CMCT increased
• MEP amplitude decreased
• Central conduction failure (triple stimulation technique)
Table 2. Motor cortex hyperexcitability and degeneration in ALS: TMS findings.
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Table 3 summarizes the TMS data on the potential mechanisms responsible for the signs of
motor cortex hyperexcitability in ALS patients. It should be mentioned that the variety of TMS
procedures makes it possible not only to reveal the dysfunction of individual mediator systems
but also to perform differentiated evaluation of neurotransmission through different types of
glutamate and GABA receptors in ALS patients.
Sign Mechanism
Decreased motor threshold • Increased glutamatergic neurotransmission
through AMPAR
• Increased sodium current due to an increase in density
and/or alteration in functional properties of sodium channels
Increased MER
amplitude
• Increased glutamatergic neurotransmission
through AMPAR
• Decreased inhibitory GABAergic neurotransmission
Decreased silent
period
• Decreased inhibitory GABAergic neurotransmission
through GABA(B) receptors
Decreased SICI • Decreased inhibitory GABAergic neurotransmission
through GABA(A) receptors
• Increased glutamatergic neurotransmission
through NMDAR
Increased ICF • Increased glutamatergic neurotransmission
through NMDAR
Table 3. Potential mechanisms of formation of TMS signs of motor cortex hyperexcitability in ALS.
Based on TMS findings, it is rather promising and reasonable to suggest that motor cortex
hyperexcitability and the underlying molecular events (e.g., excitotoxicity) cause degeneration
of motor neurons in ALS patients. We attempt to discuss the specific potential mechanisms
underlying motor cortex hyperexcitability in ALS and present the evidence for its pathogenetic
relationship with degeneration of motor neuron.
3. What does motor cortex hyperexcitability mean?
3.1. Is hyperexcitability bad?
The evidence that motor cortex hyperexcitability plays a role in pathogenesis of ALS is still
rather sparse [62]. Hyperexcitability is registered at different stages of the disease, including
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the pre-symptomatic ones [23, 45]. However, this fact tells nothing about its role in pathogen‐
esis of the disease. It is still unclear when true onset of neurodegeneration occurs; however,
the results of studies using transgenic animals demonstrate that the pathological process in
ALS may start at the earliest stages of embryogenesis (e.g., at the stage when neural networks
are formed) [63]. In this situation, all the objectively detectable alterations may be either
primary or secondary (i.e., emerge as one of nonspecific stages of neurodegeneration or via
the compensatory mechanism).
The enhancement of excitatory glutamatergic neurotransmission and reduction of inhibitory
GABAergic neurotransmission in the neocortex, which underlie hyperexcitability in ALS
patients, are believed to damage motor neurons via the excitotoxicity mechanism [4, 7]. The
role of excitotoxicity as one of the universal mechanisms causing neuronal death in various
nervous system diseases has currently been demonstrated [8, 9, 64]. High sensitivity of motor
neurons to excitotoxicity can be related to high expression of glutamate receptors and low
expression of calcium-binding proteins [9].
An important argument in favor of the role of hyperexcitability and the underlying molecular
processes in ALS pathogenesis is that this phenomenon can be early detected using TMS in
asymptomatic SOD1 mutation carriers. Vucic et al. (2008) demonstrated a decrease in SICI in
three SOD1 mutation carriers who were asymptomatic at the time the study was performed
but developed clinical signs of the disease during a prospective study within 3 years. It is
interesting that no neurophysiological signs of motor cortex excitability were revealed in 14
other asymptomatic carriers and they did not present with any clinical manifestations of the
disease within the entire study period [45]. Early development of signs of hyperexcitability of
neurons of the motor cortex, spinal cord, and even the extramotor areas such as hippocampus
(e.g., see [23]) were demonstrated in a large series of experimental studies using a culture of
neurons isolated from transgenic animals. Additional evidence is that signs of motor cortex
hyperexcitability in ALS patients can be detected before the pyramidal pathways are affected
and EMG signs of degeneration of the lower motor neuron emerge. A recent study carried out
by Menon et al. (2015) showed that 24 patients with ALS had a statistically significant decrease
in motor threshold, duration of cSP and intracortical inhibition, while simultaneously having
an increased MER amplitude and intracortical facilitation at onset of the disease [5]. No signs
of alterations in central motor conduction time (CMCT) were detected in these patients, thus
attesting to the fact that the conduction function of the pyramidal pathway was retained and
there were signs of denervation and reinnervation process according to the EMG data. The
results of this study demonstrated that motor cortex hyperexcitability precedes degeneration
of both the upper and the lower motor neurons and is the earliest neurophysiological signs of
neurodegeneration. This supports the hypothesis proposed by Charkot back in 1869 that the
upper motor neuron is the first one to be affected in ALS patients (‘dying-forward’) [65].
The certain effectiveness of riluzole in treating ALS also indirectly confirms the pathogenetic
role of hyperexcitability and excitotoxicity. Despite the diversity of its mechanisms of action,
riluzole is primarily considered to be a medication reducing excitotoxicity [66]. It has been
demonstrated that riluzole can partially normalize SICI and reduce excitability of peripheral
nerve axons in ALS patients [67].
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The indirect evidence to the pathogenetic role of excitotoxicity was also obtained in studies on
using therapeutic repetitive magnetic stimulation in ALS. High-frequency repetitive TMS
increases neuronal excitability in the stimulated area (see reviews [68] and [69]). It has been
demonstrated in a small study conducted by Di Lazzaro et al. (2004) that high-frequency
stimulation may accelerate onset of the disease, while low-frequency stimulation may inhibit
it [70]. Hence, high-frequency stimulation may increase excitotoxic degeneration of motor
neurons and motor cortex excitability, having an unfavorable effect on the course of the
disease.
3.2. Is hyperexcitability good?
Excitotoxicity and hyperexcitability have been for a long time regarded only as damaging
phenomena facilitating neuronal death. However, findings obtained in a number of studies
suggest that hyperexcitability can also have a compensatory effect, at least at early stages.
Furthermore, molecular alterations that accompany excitotoxicity are similar to the processes
taking place when neuroplasticity is ensured. We present the results of some studies confirm‐
ing the validity of this alternative view of the hyperexcitability problem in patients with ALS
and other neurodegenerative diseases.
3.2.1. Motor cortex excitability and neuroplasticity
The term ‘neuroplasticity’ means brain’s ability to alter structurally and functionally in
response to internal and external factors. This ability is currently attributed both to strength‐
ening or weakening of the existing neural connections and to the formation of new connections
or destruction of the old ones [71]. Starting with the first description of cellular mechanisms
of neuroplasticity, this universal property of neural tissue is inseparably associated with
alteration in neuronal excitability. Long-term potentiation was shown to be predominantly of
postsynaptic origin and is mostly connected to the glutamatergic system [72–74].
A series of studies have shown the alteration in motor cortex excitability and reorganization
of the cortical representation of muscles after motor learning and acquisition of new skills [75,
76]. The TMS data confirmed that there is a relationship between neuroplastic alterations and
an increase in motor cortex excitability [77–79]. Thus, Tyč and Boyadjian (2011) performed
TMS mapping of cortical representation of the deltoid and brachioradialis muscles in healthy
volunteers before and after a 6-week training (playing darts three to four times a week). The
boundaries of cortical representation of the muscles under study were expanded after training,
which was accompanied by an increase in the slope ratio of the amplitude-intensity curve,
being indicative of the increase in motor cortex excitability [80]. According to Perez et al. (2004),
a 32-minute training causes statistically significant increase in the slope ratio of the amplitude-
intensity curve and a decrease in intracortical inhibition [81]. Increased motor cortex excita‐
bility presenting as increased MER amplitude and reduced motor threshold is observed in
healthy volunteers not only after actual training but also after they had imagined the move‐
ments [82]. Professional sportsmen and musicians were found to have increased motor cortex
excitability and increased ability of the motor cortex to undergo plastic alterations [83, 84].
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To sum up, the aforementioned facts indicate that motor cortex excitability and glutamatergic
neurotransmission increase during neuroplastic alterations.
3.2.2. Hyperexcitability and neuroplasticity in pathology
The most forcible evidence for the possible relationship between hyperexcitability and
neuroplasticity was observed in patients with Alzheimer’s disease (AD). Neurodegeneration
in this disease is not limited to the structures involved in the cognitive function and affects
other brain regions as well, including the primary motor cortex. At the late stages of the disease,
AD patients often have motor disorders, including spasticity and pathologic plantar responses,
attesting to involvement of the upper motor neuron [85]. Furthermore, lesions of the motor
cortex, predominantly giant pyramidal cells of Betz, were detected in AD patients in patho‐
morphological studies [86]. In this connection, investigation of the structural and functional
status of the motor cortex in AD patients is of interest as a model of clinically asymptomatic
neurodegeneration of the motor cortex.
In AD patients, identically to those with ALS, motor cortex hyperexcitability can be recorded
using TMS. It has been demonstrated in many studies that the motor threshold decreases in
AD patients. Decreased intracortical inhibition and short cSP duration were also detected in
some studies (although not all of them) (see reviews [87, 88]). There is controversy in data on
disrupted inhibitory neurotransmission in AD patients; however, decreased SICI in AD is most
probably not associated with dysfunction of the GABAergic system [89]. The enhanced
glutamatergic neurotransmission is currently the predominant conception of the development
of motor cortex hyperexcitability in AD patients.
It is interesting to mention that motor cortex hyperexcitability in AD patients is predominantly
attributed to neuroplasticity processes. Hyperexcitability is believed to develop via the
compensatory mechanism as a response to disruption of associative connections [90].
Motor cortex hyperexcitability in AD patients is accompanied by reorganization of the cortical
representation of muscles according to TMS mapping presenting as displacement of the center
of gravity of the cortical representation in the frontomedial direction with respect to localiza‐
tion of hot spots in patients without motor disorders [90]. Ferreri et al. (2011) believe that this
may attest to plastic brain alterations aimed at maintaining normal motor activity as the neuron
number decreases progressively [91]. fMRI studies in patients at early stages of AD, identically
to those with ALS, showed areas with increased activation, which is also regarded as a result
of compensatory changes [92]. In their recent study, Guerra et al. (2015) demonstrated the
relationship between motor cortex hyperexcitability and neuroplasticity. Examination of seven
patients with vascular dementia and nine AD patients showed a statistically significant
decrease in motor threshold compared to healthy volunteers of comparable age. Parameters
related to motor cortex excitability (the area of cortical representation of muscles and the area
of active cortical points) showed a statistically significant correlation with neuroplastic
reorganization of the motor cortex assessed based on the distance between the center of gravity
of the maps and hot spot localization. The authors drew a conclusion that motor cortex
hyperexcitability may promote neuroplasticity [93].
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As opposed of the cortical motor zones, most AD patients at the dementia stage have decreased
connectivity and activation of the hippocampus, medial temporal, and prefronal cortex when
performing cognitive tasks involving short-term memory [94]. Meanwhile, activity of these
areas is increased in AD patients at the moderate cognitive impairment stage and in asymp‐
tomatic carriers of mutations in the presenilin-1 gene [95–97]. This is believed to result from
turning on of the compensatory mechanisms. It should be mentioned that transgenic animals
at the presymptomatic stage and stage of initial manifestations (which approximately corre‐
sponds to the moderate cognitive impairment stage in humans) showed an increased expres‐
sion of a number of genes promoting synaptic plasticity [98]. In particular, transgenic mice
showed enhanced expression of the AMPAR subunit genes at the early stages of the patho‐
logical process [99]. Furthermore, experimental studies revealed an increase in synaptic
plasticity and hyperexcitability in hippocampal neurons, which preceded β-amyloid deposi‐
tion [100, 101]. Schneider et al. (2001) reported that hippocampal neurons in transgenic mice
with presenilin mutation are characterized not only by hyperexcitability and reduced thresh‐
old to excitotoxic damage but also by facilitation of long-term synaptic potentiation [102]. In
their pathomorphological study, Bell et al. (2007) showed that patients with moderate cognitive
impairments had increased density of presynaptic boutons in glutamatergic synapses, while
the density of presynaptic boutons in AD patients was reduced [103]. On the contrary,
expression of the genes involved in synaptic plasticity and energy exchange was shown to
decrease at the late stages of the disease [98, 104]. These data give grounds for assuming that
the increase in neuronal excitability in AD patients at early stages of the disease may occur via
the compensatory mechanism.
3.2.3. Compensatory hyperexcitability in ALS: evidence from fundamental research
Several recently published studies using transgenic animals expressing mSOD1 have com‐
promised the conception of the pathological role of excitability of motor neurons in ALS.
Saxena et al. (2013) demonstrated that hyperexcitability can be a defense mechanism prevent‐
ing degeneration of motor neurons. Thus, reduced excitability of motor neurons decreased
accumulation of mutant SOD1, whereas increased excitability was accompanied by the greater
number of intracellular aggregates and quicker death of motor neurons. It was also demon‐
strated that mutant protein accumulation increases after AMPAR blockade and decreases
when AMPA is introduced. Stronger excitatory stimulation may contribute to the decrease in
severity of endoplasmic stress and accumulation of abnormal proteins, thus exhibiting
protective properties. Interestingly, mutant SOD1 accumulation was first detected in the least
excitable fast fatiguing (FF) motor neurons of the spinal cord [105]. Leroy et al. (2014) studied
the excitability of various populations of spinal cord motor neurons isolated from G93A
mutant mice [106]. In this study, the electrophysiological signs of hyperexcitability were
revealed only in degeneration-resistant motor neurons. The authors believe that their findings
indicate that hyperexcitability does not cause degeneration; instead, it can be a defense
mechanism [106].
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3.2.4. Neuroplasticity in ALS: evidence from fMRI studies
Nowadays, fMRI is the key method for studying neuroplasticity in ALS patients. Numerous
studies have revealed the changes in activation patterns of various brain regions in ALS both
in rest and using various paradigms [2]. In this publication, the changes in activation patterns
in ALS patients performing motor tasks are of special interest.
In the study performed by Konrad et al. (2002), ALS patients and healthy volunteers underwent
fMRI as they performed a motor paradigm (bending fingers) [107]. Significant changes in the
patterns of cortex activation were observed: a forward displacement of the activation cluster,
into the supplementary motor area, and an increase in its volume. Activation volume in the
inferior frontal gyrus (Brodmann area 6) in the contralateral hemisphere and parietal lobes
increased bilaterally. The authors have put forward a hypothesis that these changes represent
the structural and functional rearrangement of the motor system induced by degeneration of
the upper and lower motor neuron [107]. Lule et al. (2007) reported that an increase in
activation of the primary motor and premotor cortex in ALS patients is revealed not only when
performing the movement but also when imaging it [108]. Stanton et al. (2007) detected that
activation in the sensorimotor cortex (Brodmann areas 1, 2, and 4), the inferior parietal lobule,
and the superior temporal gyrus increased when the ALS patients performed a motor task,
while activation in the dorsolateral prefrontal cortex decreased [109]. It is noteworthy that
these changes were observed when comparing ALS patients not only to healthy volunteers
but also to patients with peripheral nerve disorders [109]. This confirms that involvement of
the upper motor neuron plays a crucial role in development of these changes and does not
give grounds for considering them as just a response to the development of muscle fatigue.
Thus, an analysis of the results of fMRI with the motor paradigm in ALS patients demonstrates
that the activation areas expand when a motor task is being performed. Interestingly, the
changes in activation during fMRI can have a prognostic value. Poujois et al. (2013) reported
that activation in the somatosensory and parietal cortex increases in ALS patients performing
a simple motor task compared to the control group. The dynamic follow-up for 1 year has
shown that activity of the contralateral parietal lobe has a statistically significant negative
correlation with the rate of disease progression (p = 0.001) [110].
These findings give grounds for suggesting that expansion of activation areas as an ALS patient
performs a motor task has the compensatory mechanism and is probably aimed at maintaining
the motor function in response to progressive degeneration of cortical motor neurons.
Meanwhile, certain researchers believe that the activation areas can increase due to degener‐
ation of inhibitory interneurons [2]. The relationship between alterations in activation patterns
in ALS patients according to fMRI data and changes in motor cortex excitability according to
TMS data has not been studied yet. It should be mentioned that the positive prognostic
significance of neuroplastic alterations demonstrated by Poujois et al. (2013) is in contrast with
the views about the negative role of hyperexcitability in this disease.
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4. Navigated TMS mapping in ALS
Navigated TMS (nTMS) is today considered to be the most promising method to answer the
question about the relationship between hyperexcitability and neuroplastic alterations in the
motor cortex under kinetic conditions. On the one hand, nTMS is a neuroimaging technique
and allows visualization of the location of cortical representation of certain muscles on
individual MR images and provides an opportunity to assess the changes in their size and
displacement with respect to anatomical landmarks. On the other hand, nTMS is a neurophy‐
siological method that allows one to assess various parameters showing the excitability and
degeneration of the motor cortex. The nTMS method uses the brain of a person being examined
as a landmark when applying stimuli for an individual MR model; the stimuli can be accurately
applied to a certain area with allowance for the area of interest, the individual anatomy, and
topography of the gyri [111].
In our recent study, we mapped the cortical representation of m. abductor pollicis brevis (APB)
in 30 ALS patients and 24 healthy volunteers [29]. It was demonstrated that ALS patients
exhibit a statistically significant increase in the resting motor threshold and a decrease in the
MEPs amplitude, as well as a statistically significant reduction of the volume of cortical
representation of APB (p < 0.001). The latter observation agrees with the results of the findings
of Carvalho et al. (1999) who demonstrated a progressive decrease in size of the cortical
representation in ALS patients [112]. This phenomenon is probably based on the neurodege‐
nerative process that reduces motor cortex excitability and decreases the number of cortical
motor neurons. According to our data, the volume of cortical representation statistically
significantly correlates with disease duration and negatively correlates with strength of the
corresponding muscle and disease severity according to ALS Functional Rating Scale Revised
(ALS FRS-R). These data give grounds for hypothesizing that the size of cortical representation
can be regarded as a neurophysiological marker of disease severity, which opens new avenues
for using it both in fundamental research and in clinical trials of new therapy methods. Further
studies are needed to determine the sensitivity and specificity of this marker compared to other
neurophysiological parameters and to determine its diagnostic significance.
The capabilities of navigated TMS made it possible not only to determine the size of cortical
representation but also to accurately localize the maps within the anatomic landmarks. In most
ALS patients, the maps were localized within the precentral gyrus (Brodmann area 4); some
active sites, similar to those in healthy volunteers, were detected within the postcentral gyrus
(Brodmann area 1) and the premotor cortex.
Meanwhile, we detected expanded boundaries of individual maps of the APB in some ALS
patients, usually presenting as a displacement of the greatest portion of the map toward the
postcentral gyrus. It was found by analyzing these cases that the aforementioned reorganiza‐
tion is mostly typical of patients at onset of the disease or when the disease course is relatively
benign (Figures 1 and 2). It is important to mention that the motor threshold in these cases
remained within the normal values or was decreased.
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Figure 1. Map of cortical representation of the APB in a healthy volunteer (28 years old, motor threshold—43%). Here
and in other figures, the points whose stimulation provides MEPs with amplitude over 50 μV from the contralateral
APB are shown in white.
Figure 2. Maps of cortical representation of the APB in ALS patient with the relatively benign course of the disease (54
years old, right-side motor threshold—31%, left-side motor threshold—35%, duration of the disease—25 months, APB
strength is bilaterally reduced to MRC score 4).
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Although we have not performed mathematical analysis of the relationship between motor
cortex excitability and reorganization of cortical representation, we suppose that hyperexcit‐
ability can be one of the mechanisms of the aforementioned neuroplastic alterations. Thus, a
statistically significant relationship between the passive threshold as an excitability marker
and the volume of cortical representation has been revealed. So the largest cortical represen‐
tation was revealed in patients with lower thresholds. This made it possible to rule out the
possible role of higher-intensity stimuli in expansion of the map boundaries in ALS patients
compared to the control group. Indeed, the motor threshold in some patients was 100% and
we used this intensity in mapping. However, only single MEPs were detected in the afore‐
mentioned cases and the size of cortical representation was very small (Figure 3).
Figure 3. Maps of cortical representation of the APB in a 62-year-old female patient with ALS. Upper-limb form of the
disease; disease duration—8 months. ALS-FRS-R—38. APB strength is bilaterally reduced to MRC score 2. Motor
threshold on the right and left sides—100%. The volume of cortical representation is significantly decreased.
Our findings agree with the fMRI data described above that attest to expansion of the activation
areas in ALS patients performing a motor task. Like fMRI, visual assessment of nTMS mapping
data allows one to detect displacement of cortical representation. Our preliminary data
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demonstrate that displacement of the boundaries of cortical representation as a result of
neuroplastic alterations can be caused by decreased motor cortex excitability. Hence, the
phenomenon of motor cortex hyperexcitability can have the compensatory function in ALS
patients.
5. Conclusions and future perspectives
Motor cortex hyperexcitability in ALS patients is a well-studied phenomenon that can be of
significant interest as a biomarker of neurodegeneration. However, despite the large number
of studies, the reasons and sequelae currently remain poorly studied. Since motor cortex
hyperexcitability in ALS patients was first described, this phenomenon has been attributed to
the development of excitotoxicity and weakening of inhibitory neurotransmission in the
neocortex, thus ensuring its pathogenetic role in the development of neurodegeneration.
However, no direct evidence to the fact that motor cortex hyperexcitability in ALS patients
attests to development of excitotoxicity and precedes its degeneration has been obtained yet.
Meanwhile, hyperexcitability can be one of the mechanisms of neuroplastic alterations, thus
having the compensatory (sanogenetic) rather than pathogenetic value. This theory has been
supported by the data on interaction between decreased motor cortex excitability and neuro‐
plasticity in the norm and in some pathologic conditions such as Alzheimer’s disease and
vascular dementia. Furthermore, expansion of the cortical representation of certain muscles
was demonstrated for ALS patients in fMRI and nTMS studies, which can be a manifestation
of neuroplasticity and related to increased motor cortex excitability.
It should be mentioned that hyperexcitability is not a specific sign of ALS and is also revealed
in other neurodegenerative diseases. More and more data supporting the similarity between
pathophysiology of neurodegeneration in various diseases and its relationship with intracel‐
lular accumulation of abnormal proteins have been obtained. This may result in dysfunction
of synaptic connections and a compensatory increase in expression of the genes ensuring
increased excitability and synaptic plasticity.
A hypothesis can be put forward based on these data that hyperexcitability plays different
roles at different stages of the disease (Figure 4). At onset of the disease, this phenomenon can
develop via the compensatory mechanism in response to reduced number of functioning
motor neurons and disruption of synaptic connections. Hence, increased hyperexcitability can
be regarded as a method for maintaining functioning of the system as the number of its
components decreases. In addition, hyperexcitability can have a protective effect at the cellular
level as it prevents accumulation of pathologically altered proteins. As the disease progresses,
hyperexcitability may start to have a pathological effect and induce excitotoxicity. Does this
mean that our effect on motor cortex excitability in ALS patients needs to be differentiated
depending on disease stage? Further research involving various methods and focusing on
patients at different stages of the disease needs to be carried out to answer this question.
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Figure 4. A link between excitability and function.
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